We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genentech Settles Rituxan Case for $20 Million
Genentech Settles Rituxan Case for $20 Million
December 9, 2011
Genentech has agreed to pony up $20 million to the U.S. government to settle a qui tam suit alleging kickbacks for off-label promotion of its cancer drug Rituxan.